Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Daniels, Stephen R.; Gidding, Samuel S.; Ferranti, Sarah D. de

doi:10.1016/j.jacl.2011.03.453

Cited by 163 publications

(150 citation statements)

References 84 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…A telehealth programme should be employed for remote care [8,197]. Children are best reviewed in a specialist paediatric clinic, with appropriate arrangement made for transitional care [8,18,20,65];…”

Section: Organization and Development Of Carementioning

confidence: 99%

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Watts

Gidding

Wierzbicki

et al. 2014

International Journal of Cardiology

329

200

View full text Add to dashboard Cite

Section: Organization and Development Of Carementioning

confidence: 99%

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Watts

Gidding

Wierzbicki

et al. 2014

International Journal of Cardiology

329

200

View full text Add to dashboard Cite

“…Most such patients will have a mutation in one of three genes: LDL receptors (familial hypercholesterolemia); PCSK-9; or apolipoprotein B. Because of the high lifetime risk of patients with familial hypercholesterolemia, attention must be given from an early age to effective cholesterol lowering (National Institute for Health and Clinical Excellence 2008; Daniels et al 2011;Goldberg et al 2011;Watts et al 2011). Other cases of severe hypercholesterolemia likely will have polygenic hypercholesterolemia.…”

Section: Specific Forms Of Dyslipidemia In Primary Preventionmentioning

confidence: 99%

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Grundy

2013

Journal of Clinical Lipidology

151

View full text Add to dashboard Cite

“…En nuestro medio, los médicos pediatras especialistas en Nutrición infantil serían los recomendados. 14,30,31 Los fármacos utilizados en el tratamiento de las dislipidemias se agrupan de la siguiente manera:…”

Section: Tratamiento Farmacológicounclassified

Consenso sobre manejo de las dislipidemias en pediatría

Nutrición¹

2015

Arch Argent Pediat

View full text Add to dashboard Cite

RESUMENEste documento, dirigido a médicos pediatras, de familia, especialistas en nutrición, entre otros, tiene por objetivos trasmitir los lineamientos para el diagnóstico temprano y el tratamiento de dislipidemias en pediatría y concientizar al pediatra sobre la prevención de la enfermedad cardiovascular del adulto. La aterosclerosis es un proceso progresivo, que comienza en la infancia, y las dislipidemias pertenecen al grupo de factores de riesgo que aceleran su evolución. Se propone el tamizaje universal de dislipidemias a los 6 años y a los 17 años, y selectivo a partir de los 2 años si existen factores de riesgo o enfermedad predisponente. Se recomienda el dosaje de colesterol total, LDL, HDL y triglicéridos con ayuno previo. El tratamiento de las dislipidemias en pediatría tiene el objetivo de disminuir el riesgo de eventos cardiovasculares prematuros en el caso de hipercolesterolemias y disminuir el riesgo de pancreatitis en el caso de hipertrigliceridemias graves. El pediatra deberá abordar el tamizaje, diagnóstico e implementación de medidas hipolipemiantes. Los pacientes con niveles más elevados deberán derivarse a especialistas con experiencia en tratamientos farmacológicos. Palabras clave: dislipidemias, hipercolesterolemia, hipertrigliceridemia, tamizaje, tratamiento. ABSTRACTThis document is intended for pediatricians, family, nutritionists and others. It aimed to convey the guidelines for early diagnosis and treatment of dyslipidemia in children and sensitize the pediatrician to the prevention of cardiovascular disease in adults. Atherosclerosis is a gradual process that begins in childhood and dyslipidemia belongs to the group of risk factors that accelerate their evolution. Universal screening for dyslipidemia at 6 years and 17 years is proposed; selective screening after 2 years is recommended if there are risk factors or predisposing disease. Assay of total cholesterol, LDL, HDL and triglycerides is recommended, prior fasting. Treatment of dyslipidemia in children aims to reduce the risk of premature cardiovascular events in the case of hypercholesterolemia, and decreasing the risk of pancreatitis in the case of severe hypertriglyceridemia. The pediatrician should address screening, diagnosis and implementation of lipid-lowering measures. Patients with higher levels should be referred to specialists with expertise in drug therapy.

show abstract

Pediatric aspects of Familial Hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia

Cited by 163 publications

References 84 publications

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia

Consenso sobre manejo de las dislipidemias en pediatría

Contact Info

Product

Resources

About